ArticleJournal of medicinal chemistry2016
Small Antimicrobial Agents Based on Acylated Reduced Amide Scaffold.
Article in Journal of medicinal chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 59 citations in OpenAlex.
- Quinoline-2-one derivatives as promising antibacterial agents against multidrug-resistant Gram-positive bacterial strains.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Global Trends in Research of Antimicrobial Peptides for the Treatment of Drug-Resistant Bacteria from 1995 to 2021: A Bibliometric Analysis.Infection and drug resistance · 2023Article
- Article
- Antimicrobial Peptide Mimics for Clinical Use: Does Size Matter?Frontiers in immunology · 2022Review
- Dimeric lipo-α/sulfono-γ-AA hybrid peptides as broad-spectrum antibiotic agents.Biomaterials science · 2021Article
- Development of Bis-cyclic Imidazolidine-4-one Derivatives as Potent Antibacterial Agents.Journal of medicinal chemistry · 2020Article
- Challenges in the development of next-generation antibiotics: opportunities of small molecules mimicking mode of action of host-defense peptides.Expert opinion on therapeutic patents · 2020Article
- γ-AApeptides-based Small Molecule Ligands That Disaggregate Human Islet Amyloid Polypeptide.Scientific reports · 2020Article
- Dimeric γ-AApeptides With Potent and Selective Antibacterial Activity.Frontiers in chemistry · 2020Article
- Lipidated α/Sulfono-α-AA heterogeneous peptides as antimicrobial agents for MRSA.Bioorganic & medicinal chemistry · 2020Article
- Short Cationic Peptidomimetic Antimicrobials.Antibiotics (Basel, Switzerland) · 2019Review
- Modulation of S. aureus and P. aeruginosa biofilm: an in vitro study with new coumarin derivatives.World journal of microbiology & biotechnology · 2018Article
- Developments with investigating descriptors for antimicrobial AApeptides and their derivatives.Expert opinion on drug discovery · 2018Review
- Facilely accessible quinoline derivatives as potent antibacterial agents.Bioorganic & medicinal chemistry · 2018Article
- Promising Antibiofilm Activity of Peptidomimetics.Frontiers in microbiology · 2018Review
- Novel bis-cyclic guanidines as potent membrane-active antibacterial agents with therapeutic potential.Chemical communications (Cambridge, England) · 2017Article
- Membrane-Active Hydantoin Derivatives as Antibiotic Agents.Journal of medicinal chemistry · 2017Article
- Modulation of lipid membrane structural and mechanical properties by a peptidomimetic derived from reduced amide scaffold.Biochimica et biophysica acta. Biomembranes · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
Prevalence of drug-resistant bacteria has emerged to be one of the greatest threats in the 21st century. Herein, we report the development of a series of small molecular antibacterial agents that are based on the acylated reduced amide scaffold. These molecules display good potency against a panel of multidrug-resistant Gram-positive and Gram-negative bacterial strains. Meanwhile, they also effectively inhibit the biofilm formation. Mechanistic studies suggest that these compounds kill bacteria by compromising bacterial membranes, a mechanism analogous to that of host-defense peptides (HDPs). The mechanism is further supported by the fact that the lead compounds do not induce resistance in MRSA bacteria even after 14 passages. Lastly, we also demonstrate that these molecules have therapeutic potential by preventing inflammation caused by MRSA induced pneumonia in a rat model. This class of compounds could lead to an appealing class of antibiotic agents combating drug-resistant bacterial strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.